CancerDrs

Lung Cancer clinical trials in Florida

84 actively recruiting lung cancer trials at 58 sites across Florida.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Florida:
  • Bay Pines VA Healthcare System — Bay Pines, Florida
  • Morton Plant Hospital — Clearwater, Florida
  • Halifax Health Cancer Center for Hope - Daytona Beach — Daytona Beach, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
  • Mayo Clinic in Florida — Jacksonville, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Florida:
  • Moffitt Cancer Center-International Plaza — Tampa, Florida
  • Moffitt Cancer Center - McKinley Campus — Tampa, Florida
  • Moffitt Cancer Center — Tampa, Florida
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Florida:
  • GenesisCare USA — Aventura, Florida
  • Bay Pines Veterans Affairs Healthcare System — Bay Pines, Florida
  • Local Institution - 007-922-A — Bonita Springs, Florida
  • Local Institution - 007-922-D — Bradenton, Florida
  • Local Institution - 007-922-E — Cape Coral, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Florida:
  • Millennium Oncology Research Clinic — Hollywood, Florida
  • University of Florida - Jacksonville — Jacksonville, Florida
  • Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
  • Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala — Ocala, Florida
  • Orlando Health Cancer Institute — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Florida:
  • Clinical Study Site — Fort Lauderdale, Florida
  • Clinical Study Site — Hialeah, Florida
  • Clinical Study Site — Jacksonville, Florida
  • Clinical Study Site — Miami, Florida
  • Clinical Study Site — North Venice, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…

Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in Florida:
  • Florida Cancer Specialists & Research Institute (FCS)-East — Fort Myers, Florida
  • BioResearch Partner- Hialeah Hospital — Hialeah, Florida
  • Mayo Clinic — Jacksonville, Florida
  • Cancer Specialists of North Florida — Jacksonville, Florida
  • Ocala Oncology — Ocala, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Florida:
  • Research Site — Clermont, Florida
  • Research Site — Gainesville, Florida
  • Research Site — Miami Beach, Florida
  • Research Site — Orange City, Florida
  • Research Site — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable gen…

Sponsor: AstraZeneca
NCT ID: NCT07291037
Sites in Florida:
  • Research Site — Fort Myers, Florida
  • Research Site — Jacksonville, Florida
  • Research Site — St. Petersburg, Florida
  • Research Site — Tampa, Florida
  • Research Site — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Sponsor: Amgen
NCT ID: NCT07005128
Sites in Florida:
  • Florida Oncology and Hematology — Fort Myers, Florida
  • Cancer Specialists of North Florida - Southpoint — Jacksonville, Florida
  • Orlando Health Cancer Institute — Kissimmee, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Florida:
  • The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156) — Fort Lauderdale, Florida
  • Miami Cancer Institute at Baptist Health, Inc. ( Site 0214) — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Florida:
  • University of Miami Hospital and Clinics, Sylvester Cancer Center — Miami, Florida
  • Memorial Hospital West — Pembroke Pines, Florida
  • Florida Cancer Specialists - North — St. Petersburg, Florida
  • Local Institution - 0477 — Tamarac, Florida
  • Florida Cancer Specialists - East — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/…

Sponsor: OncoC4, Inc.
NCT ID: NCT05671510
Sites in Florida:
  • D&H Cancer Research Center LLC - 1153 — Margate, Florida
  • Ocala Oncology Center PL - 1102 — Ocala, Florida
  • AdventHealth Cancer Institute - 1105 — Orlando, Florida
  • Orlando Health - 1130 — Orlando, Florida
  • Florida Cancer Specialists -South - 1126 — Sarasota, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…

Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Florida:
  • University of Florida (Adults and Pediatrics) — Gainesville, Florida
  • University of Miami/Jackson Memorial Hospital (Adults only) — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in Florida:
  • Research Site — Jacksonville, Florida
  • Research Site — Ocala, Florida
  • Research Site — Orange City, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation thera…

Sponsor: Shanghai Junshi Bioscience Co., Ltd.
NCT ID: NCT06095583
Sites in Florida:
  • Florida Cancer Specialists Pan Handle — Fort Myers, Florida
  • Florida Cancer Specialists South — Fort Myers, Florida
  • USA029 University of Miami Sylvester Comprehensive Cancer Center 1550 NW 10th Avenue 33173 Miami FL Ikpeazu Chukwuemeka N — Miami, Florida
  • Mid-Florida Hematology Oncology — Orange City, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…

Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Florida:
  • Boca Raton Regional — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of meta…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06422143
Sites in Florida:
  • Mid Florida Hematology and Oncology Center ( Site 0109) — Orange City, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no pr…

Sponsor: Daiichi Sankyo
NCT ID: NCT06899126
Sites in Florida:
  • Bay Pines VA Healthcare System — Bay Pines, Florida
  • Lynn Cancer Institute Center — Boca Raton, Florida
  • Holy Cross Hospital — Fort Lauderdale, Florida
  • Mid-Florida Hematology & Oncology Centers, P.A. — Orange City, Florida
  • BRCR Global Plantation — Plantation, Florida
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and ef…

Sponsor: AbbVie
NCT ID: NCT06236438
Sites in Florida:
  • Memorial Hospital West /ID# 262221 — Pembroke Pines, Florida
  • Bond Clinic /ID# 262611 — Winter Haven, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in Florida:
  • Mount Sinai Cancer Center ( Site 0137) — Miami Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The g…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07190248
Sites in Florida:
  • Mount Sinai Cancer Center ( Site 0137) — Miami Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging …

Sponsor: Vergent Bioscience, Inc.
NCT ID: NCT07499674
Sites in Florida:
  • Orlando Health Cancer Center — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally. This study focuses o…

Sponsor: Takeda
NCT ID: NCT07217301
Sites in Florida:
  • D & H Cancer Research Center — Margate, Florida
  • BRCR Global — Tamarac, Florida
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Sit…

Sponsor: Privo Technologies
NCT ID: NCT05893888
Sites in Florida:
  • Miami Cancer Institute — Miami, Florida
View on ClinicalTrials.gov →

Showing 25 of 84 trials with sites in Florida. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07